Cleancard provides home cancer testing services that utilize synthetic biology and artificial intelligence to detect biomarkers for prostate, bladder, and ovarian cancers. This technology enables patients to receive accurate cancer diagnostics and treatment options conveniently from their homes.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
UIFounders
Product
Problem
Current methods for cancer detection often require invasive procedures, specialized medical facilities, and significant wait times for results, creating barriers to early diagnosis and treatment. This can lead to delayed intervention and potentially poorer outcomes for patients.
Solution
Cleancard is developing at-home cancer testing services that leverage synthetic biology and artificial intelligence to detect cancer biomarkers. The company aims to provide a convenient and accessible method for individuals to screen for prostate, bladder, and ovarian cancers from the comfort of their homes. By combining advanced biological sensors with AI-powered analysis, Cleancard seeks to offer accurate and timely diagnostic information, potentially enabling earlier detection and more effective treatment strategies. The company's approach focuses on simplifying the testing process and improving access to cancer screening.
Target Audience
The primary target audience includes individuals seeking convenient and accessible cancer screening options, as well as those at higher risk for prostate, bladder, or ovarian cancers.
Features
- At-home sample collection for cancer biomarker detection
- Synthetic biology-based sensors for enhanced sensitivity and specificity
- Artificial intelligence algorithms for data analysis and result interpretation
- Detection of biomarkers for prostate, bladder, and ovarian cancers